Oncology · Chemotherapy
The FDA's approval of Daito's Methotrexate Sodium ANDA213362 is significant as it strengthens Daito's competitive position in the oncology market. Pharma companies should evaluate the implications for their own generic offerings and pricing strategies in response to this development.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/20/2026, 6:33:03 PM
Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Daito's Methotrexate Sodium ANDA213362 is significant as it strengthens Daito's competitive position in the oncology market. Pharma companies should evaluate the implications for their own generic offerings and pricing strategies in response to this development. Regulatory context from FDA (FDA AP — METHOTREXATE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 27 ranked evidence items (8 high-relevance).
Portfolio teams should assess the impact of this approval on market share and pricing strategies for Methotrexate Sodium. The strongest clinical anchor is Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 7 regulatory and 4 competitive items passed relevance filtering for Daito.
The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ). This approval may enhance Daito's position in the oncology market, particularly in the generic segment of chemotherapy agents.
Regulatory risk is concentrated around FDA AP — METHOTREXATE SODIUM (ORIG) (FDA). Entity match (methotrexate sodium); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but ongoing monitoring of Daito's launch and market strategies will be essential to assess further regulatory implications.
FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — SODIUM BICARBONATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — SODIUM BICARBONATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceTesting Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRelationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFollow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceElectroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceCombination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePalliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Datopotamab Deruxtecan Supplement
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Tecentriq Hybreza Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEarly prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEconomic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceNeoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceTrial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceType 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceColorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Daito's Methotrexate Sodium ANDA213362 is significant as it strengthens Daito's competitive position in the oncology market. Pharma companies should evaluate the implications for their own generic offerings and pricing strategies in response to this development.
This approval could lead to increased market share for Daito in the generic chemotherapy segment, potentially impacting pricing dynamics and revenue for other competitors in the market.
The approval status indicates compliance with FDA standards, but ongoing monitoring of Daito's launch and market strategies will be essential to assess further regulatory implications.
Monitor for the launch timeline and market entry strategies from Daito following this approval.
Track for follow-up milestones; no immediate action required.